Frank Hennecke is Chief Technical Officer at AMYRA.
Frank has over 20 years of experience in biopharmaceutical drug development, production, and clinical supply. In this time, he successfully advanced over 20 investigational drug candidates into pre-clinical and clinical studies.
He held executive positions in several biotech companies, both publicly-traded and privately owned in Switzerland, Germany and the US.
Until end 2017 he was CTO of Rigontec GmbH/ Germany, which in October 2017 was acquired by MSD.
Frank holds a PhD in Biology (Göttingen) and held post-doc positions in molecular genetics (Göttingen) and biochemistry (ETH Zurich). He is also a Quality Responsible Person (FvP; Swiss equivalent to European Qualified Person).